Ildong Pharmaceutical said Wednesday it released a new hyaluronic acid filler Hyaleve Series and began full-scale marketing.

Hyaleve Series is a medical device for tissue repair and wrinkle improvement. The treatment contains a non-animal and sterile hyaluronic acid derivative, which was obtained through a microbial culture, and lidocaine, a local anesthetic for pain relief, according to Ildong.

Hyaleve Series comes in four types depending on the particle size – Hyaleve No. 1, Hyaleve No. 2, Hyaleve No. 3, and Hyaleve No. 4.

Ildong said Hyaleve uses a 3 million Dalton high-molecular, high-viscosity derivative. The company confirmed Hyaleve’s excellent volume and duration in a clinical trial, it said.

The new product uses the “multiple mixing cross-linking technology (MMCT),” owned by Ildong Hyaltech, an affiliate of Ildong Holdings, which raised the bonding efficacy and uniformity of the hyaluronic acid and the crosslinking agent, Ildong said.

Using a patented cleansing method, the company effectively removes the leftover crosslinking agent after manufacturing. This raised the purity and safety of the hyaluronic acid raw materials, Ildong added.

The syringe has a butterfly-shaped double grip to provide a stable grip and help easy use and pressure control during an injection.

“We will promote Hyaleve to dermatology and plastic surgery clinics in the aesthetic market and work with Ildong Hyaltech to continue developing various raw materials and products related to hyaluronic acid,” an official at Ildong Pharmaceutical said.